In 2019, approximately 61 men and 43 women per 100,000 population died from lung cancer in England. The North East of England had the highest mortality from lung cancer for both genders with a rate of approximately 80 men and 66 women per 100,000 population.

This release summarises the diagnoses in 2019 registered by NDRS covering all registerable neoplasms (all cancers, all in situ tumours, some benign tumours and all tumours that have uncertain or unknown behaviours)

In the period 2017 to 2019, the mortality rate from melanoma skin cancer in the United Kingdom was 4.8 deaths per 100,000 for men and 2.8 deaths per 100,000 for women. Across the overall provided time interval the mortality rate from skin cancer has increased significantly in the UK, although there has been a slight decline since 2012-2014.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

In the period 2017 to 2019, the mortality rate from kidney cancer in the United Kingdom was 10.4 deaths per 100,000 men and 5.1 deaths per 100,000 women. Across the overall provided time interval the mortality rate from kidney cancer has increased in the UK, although the rate has been fairly stable in recent years.

In 2018/19, the mortality rate from non-melanoma skin cancer in the United Kingdom was 2.3 deaths per 100 thousand for men and 0.8 deaths per 100 thousand for women. Across the provided time interval the mortality rate from non-melanoma skin cancer has decreased for women, while the rate for men has experienced more fluctuations but was a higher rate at the start and the end of the provided time interval.

In 2021, approximately 666 males per 100,000 and 557 females per 100,000 in England were newly diagnosed with cancer, excluding non-melanoma skin cancer. Overall, the diagnosis rate for males showed a slight decreasing trend over the years, while the rate for females remained relatively stable with minor changes. This statistic shows the rate of newly diagnosed cases of cancer per 100,000 population in England from 2018 to 2021, by gender.

This statistic shows the number of deaths from cervical cancer in England from 2014 to 2021. In 2021, the number of deaths from cervical cancer reached 702, an increase from 681 deaths in 2020.

Directly age standardised mortality rate from breast cancer for females in the respective time period per 100,000 registered female patients. October 2022: This is the last CCGOIS publication. All Clinical Commissioning Groups (CCGs) were statutorily abolished on the 1 July 2022, and from this point all statutory obligations are managed by the Integrated Care Boards (ICBs). ICBs were established as statutory bodies from July 2022 and succeed Sustainability and Transformation Partnerships (STPs). These came into effect on 1 July 2022. A transition phase has been implemented from 1 July 2022, during which the 106 Organisation Data Service (ODS) codes that identified CCGs will be temporarily retained, but the names will be changed to identify the ‘Sub ICB Location’. March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published for 2016-2018 only; all data is based on the most recent methodology. For the historic time series of this indicator please refer to the zip files in the June 2018 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---june-2018 Please note, neither version of the file contains data for 2015-2017; changes in the data processing meant the 2015 data was not comparable to the 2016 and 2017 data processed under the new method. 2) Data are run against CCGs which were in existence at the time of processing. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the June 2018 publication referenced above. Legacy unique identifier: P01819

This statistic shows the amount of registrations of newly diagnosed cases of lung cancer in England in 2021, by age group and gender. In this year, almost four thousand cases were reported among men aged 70 to 74 years. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to lung cancer.

Directly age standardised mortality rate from breast cancer for females in the respective time period per 100,000 registered female patients. March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published for 2016-2018 only; all data is based on the most recent methodology. For the historic time series of this indicator please refer to the zip files in the June 2018 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---june-2018 Please note, neither version of the file contains data for 2015-2017; changes in the data processing meant the 2015 data was not comparable to the 2016 and 2017 data processed under the new method. 2) Data are run against CCGs which were in existence at the time of processing. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the June 2018 publication referenced above. Legacy unique identifier: P01819

In 2021, 172.9 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration, and a steep rise from the drop in the rate of registration reported in 2020. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2021.

Breast cancer is a disease which affects much more women than men. In England in 2022, over 50 thousand new cases of breast cancer were registered among women. The most affected age group was women aged 65 to 69 years of age with over 6.3 thousand cases reported.

Excess Under 75 Mortality Rates in Adults With Serious Mental Illness, Excess under 75 mortality rates in adults with serious mental illness - 2019 to 2021 This indicator is a measure of the extent to which adults with a serious mental illness (SMI) die younger than adults without a serious mental illness (nSMI). To measure premature mortality in adults diagnosed with a serious mental illness (SMI).

Snapshot img

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size 2025-2029

The epidermal growth factor receptor (egfr) inhibitors market size is forecast to increase by USD 10.73 billion at a CAGR of 10.5% between 2024 and 2029.

The EGFR Inhibitors Market is witnessing significant growth due to the rising prevalence of major cancer indications, particularly lung, breast, and colorectal cancers. According to the American Cancer Society, an estimated 1.9 million new cancer cases and over 600,000 cancer deaths are projected in the US alone for 2021. The increase in research areas for the treatment of various types of cancer, including the development of targeted therapies, further fuels market growth. However, the high treatment costs associated with EGFR inhibitors remain a significant challenge. Despite these costs, the market presents substantial opportunities for companies seeking to capitalize on the unmet medical needs and advancements in cancer research. Strategic collaborations, regulatory approvals, and product pipeline developments are key areas of focus for market participants to navigate the competitive landscape effectively. Companies can also explore cost-effective manufacturing strategies and pricing models to address the affordability concerns and expand their customer base. Overall, the EGFR Inhibitors Market is poised for continued growth, driven by the increasing burden of cancer and the ongoing research efforts to develop more effective and affordable treatment options.

What will be the Size of the Epidermal Growth Factor Receptor (EGFR) Inhibitors Market during the forecast period?

Request Free SampleThe EGFR inhibitor market encompasses a range of small molecule inhibitors designed to target and inhibit the epidermal growth factor receptor (EGFR), a transmembrane protein involved in cell growth and survival. These inhibitors play a significant role in cancer therapy, particularly in the treatment of various types of cancer, including lung and liver cancer. The market's growth is driven by the increasing prevalence of EGFR mutations responsible for cancer progression and the clinical utility of these inhibitors in addressing these mutations. EGFR inhibitors function by binding to the target kinases, disrupting their interactions and subsequent signaling pathways, ultimately leading to cytotoxicity and inhibition of cancer cell growth. The market includes several subclasses of EGFR inhibitors, such as irreversible and reversible inhibitors, each with distinct chemical structures and pharmacological uses. Metabolites and excretion mechanisms, including glutathione and cysteine, also influence the efficacy and safety of these inhibitors. Ongoing research focuses on optimizing synthetic routes and crystal structures to enhance binding modes and improve therapeutic outcomes.

How is this Epidermal Growth Factor Receptor (EGFR) Inhibitors Industry segmented?

The epidermal growth factor receptor (egfr) inhibitors industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. IndicationLung cancerColorectal cancerBreast cancerOthersDistribution ChannelRetail pharmaciesHospital pharmaciesOnline pharmaciesGeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAsiaRest of World (ROW)

By Indication Insights

The lung cancer segment is estimated to witness significant growth during the forecast period.Lung cancer is a deadly disease accounting for the highest number of cancer-related deaths worldwide. With over 1.8 million estimated new cases and 1.6 million deaths annually, it surpasses other major cancer indications such as colorectal, prostate, ovarian, and breast cancer combined. Lung cancer can be categorized into two major types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). EGFR inhibitors have emerged as a promising therapeutic approach for NSCLC, particularly in cases with specific mutations. These small molecule inhibitors target the EGFR kinase, interrupting its signaling pathway and inhibiting cell growth. Erlotinib, imatinib, afatinib, brigatinib, dacomitinib, neratinib, osimertinib, pyrotinib, vandetanib, icotinib, almonertinib, simotinib, and olmutinib are some notable EGFR inhibitors. These inhibitors interact with the EGFR receptor, a transmembrane protein, through various bonding modes, including Michael acceptor and hydrogen bonding. Their pharmacological uses include both clinical and preclinical applications. The chemical structures and crystal structures of these inhibitors have been extensively studied to understand their binding modes, interactions, cytotoxicity, metabolites, and excretion mechanisms. Mutations in responsible genes, such as EGFR, HER2, and KRAS, can lead to overexpression of these receptors, making them

In 2021, 10 males and 6.3 females per 100,000 population in England were registered as newly diagnosed with brain cancer. Compared to the previous year, a slight increase in the newly diagnosed thyroid cancer rates was seen for male individuals, while the female diagnose rate remained stable. This statistic shows the rate of newly diagnosed cases of brain cancer per 100,000 population in England from 1995 to 2021, by gender.

A measure of the proportion of children diagnosed with any type of cancer in a year who are still alive five years after diagnosis. This indicator attempts to capture the success of the NHS in preventing children from dying once they have been diagnosed with any type of cancer. As of November 2019, please refer to the data tables published by the Office for National Statistics (ONS) available via the resource link below. Please ensure the latest data period is selected. The data for the indicator is displayed in Table 5 of the excel file. Legacy unique identifier: P01744